New Quest Vantage Cancer Panels

Quest Diagnostics expanded its Vantage cancer test menu with three new services: the MYvantage 34-gene Hereditary Comprehensive Cancer Panel, which includes 34 high risk, moderate risk, and emerging risk genes associated with a broad spectrum of hereditary cancers; the Glvantage Hereditary Colorectal Cancer Test, which includes 13 genes predominantly associated with colon and gastric cancers; and the Qvantage Hereditary Women's Health Cancer Test, which includes 14 genes predominantly associated with breast, colon, uterine, and ovarian cancers. Each tests only include genes that meet certain criteria, such as two-fold increased cancer risk, association with a disease syndrome for which cancer may occur, and guideline support for genetic counseling, the company said.